Updates are available Correction dated 2026-04-21
Click to view Correction: https://doi.org/10.1007/s41669-026-00648-9
-
Authors
Rodríguez-Lago, Iago
Peinado-Fabregat, José Ignacio
Guigini, Marcelo
Cerezales, Mónica
Ibáñez, Francisco https://orcid.org/0009-0008-5986-7158
Crespo, Carlos
Barreiro-de Acosta, Manuel
-
Funding
Funding for this research was provided by:
Fresenius Kabi España SAU
Eusko Jaurlaritza (2020111061/2023222006)
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 16 February 2026
First Online: 9 March 2026
Change Date: 2 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: the name of the author Manuel Barreiro-de Acosta was incorrectly given as just ‘Barreiro-de Acosta’.
Change Date: 21 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s41669-026-00648-9
Declarations
:
: Study concept and design: JIPF, MG, MC, CC. Statistical analysis: FI, CC. Data interpretation: MC, FI, CC. Drafting of the manuscript: MC, FI. Critical revision of the manuscript for important intellectual content: IRL, JIPF, MG, CC, MBA. Study supervision: JIPF, MG, CC.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.
: IRL has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Alfasigma, Biogen, Chiesi, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Johnson & Johnson, Eli Lilly, Mirum Pharmaceuticals, Merck, Pfizer, Roche, Takeda, and Tillotts Pharma. Research support from AbbVie. MBA has been speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Alphasigma, Lilly, Pfizer, Sandoz, Biocon, Abivax, Fresenius, Faes Farma, Ferring, Tillots, Chiesi, Adacyte, Diasorin, Oncostellae and SunRock. JIPF and MG are employees of Fresenius Kabi España. MC, FI, and CC are employees of Axentiva Solutions S.L., a consultancy firm that works for several pharmaceutical and medical devices companies.
: Not applicable.
: The model code is proprietary and subject to intellectual property restrictions; therefore, it is not available for public distribution. Access was provided to the editors and reviewers solely for the peer-review process.
: Not applicable.
: Not applicable.
